Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Designed for in-vitro for treatment of sperm in conjunction with intrauterine insemination and in-vitro fertilization procedures
Subscribe to our email newsletter
Cordex has signed an agreement with Clinical Trials International (CTI), regarding a license to develop and market Cordex’s drug candidate ATPotent.
ATPotent is a novel ATP-based drug candidate designed for in vitro for the treatment of sperm in conjunction with intrauterine insemination (IUI) and in vitro fertilization (IVF) procedures.
Under the agreement, CTI has obtained exclusive rights for the clinical development and marketing of ATPotent in EU, Russia and Ukraine.
Cordex will have access to the clinical data to be obtained in the study to support the development of ATPotent in the rest of the world.
James S. Kuo, Chairman and CEO of Cordex, said: We are pleased to enter this agreement with CTI as we feel it will accelerate the development of ATPotent as a novel treatment for the majority of male infertility cases in the US and other parts of the world.